Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0E8PR
|
||||
| Former ID |
DIB014883
|
||||
| Drug Name |
BAY1163877
|
||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Phase 1 | [1] | ||
| Company |
Bayer healthcare pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Fibroblast growth factor receptor | Target Info | Antagonist | [2] | |
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01976741) Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor. U.S. National Institutes of Health. | ||||
| REF 2 | Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. Cancer Research. 10/2014; 74(19 Supplement):1739-1739. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.